Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Centiloid recommendations for clinical context-of-use from the AMYPAD consortium

Collij, Lyduine E. LU ; Bollack, Ariane ; La Joie, Renaud ; Shekari, Mahnaz ; Bullich, Santiago ; Roé-Vellvé, Núria ; Koglin, Norman ; Jovalekic, Aleksandar ; Garciá, David Valléz and Drzezga, Alexander , et al. (2024) In Alzheimer's and Dementia 20(12). p.9037-9048
Abstract

Amyloid-PET quantification through the tracer-independent Centiloid (CL) scale has emerged as an essential tool for the accurate measurement of amyloid-β (Aβ) pathology in Alzheimer's disease (AD) patients. The AMYPAD consortium set out to integrate existing literature and recent work from the consortium to provide clinical context-of-use recommendations for the CL scale. Compared to histopathology, visual reads, and cerebrospinal fluid, CL quantification accurately reflects the amount of AD pathology. With high certainty, a CL value below 10 excludes the presence of Aβ pathology, while a value above 30 corresponds well with pathological amounts. Values falling in between these two cutoffs (“intermediate range”) are related to an... (More)

Amyloid-PET quantification through the tracer-independent Centiloid (CL) scale has emerged as an essential tool for the accurate measurement of amyloid-β (Aβ) pathology in Alzheimer's disease (AD) patients. The AMYPAD consortium set out to integrate existing literature and recent work from the consortium to provide clinical context-of-use recommendations for the CL scale. Compared to histopathology, visual reads, and cerebrospinal fluid, CL quantification accurately reflects the amount of AD pathology. With high certainty, a CL value below 10 excludes the presence of Aβ pathology, while a value above 30 corresponds well with pathological amounts. Values falling in between these two cutoffs (“intermediate range”) are related to an increased risk of disease progression. Together, CL quantification is a valuable adjunct to visual assessments of amyloid-PET images. An abnormal amyloid biomarker assessment is a key criterion to determine eligibility for anti-amyloid disease-modifying therapies, and amyloid-PET quantification can add further value by precisely monitoring amyloid clearance, and hence guiding patient management decisions. Highlights: Centiloid (CL) quantification robustly reflects of the amount of Aβ pathology. CL < 10/CL > 30 reflects Aβ-negativity/positivity thresholds with high certainty. CL quantification is a valuable adjunct to visual assessments of amyloid-PET. CL quantification can support trial design and treatment management. CL quantification could support the identification of early or emerging Aβ pathology.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; and (Less)
author collaboration
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Amyloid-β, Centiloid quantification, clinical trials, positron emission tomography
in
Alzheimer's and Dementia
volume
20
issue
12
pages
12 pages
publisher
Wiley
external identifiers
  • pmid:39564918
  • scopus:85210017038
ISSN
1552-5260
DOI
10.1002/alz.14336
language
English
LU publication?
yes
id
7d795f86-ac98-48f9-88f9-25000f8513e8
date added to LUP
2025-01-15 15:21:52
date last changed
2025-07-17 19:51:14
@article{7d795f86-ac98-48f9-88f9-25000f8513e8,
  abstract     = {{<p>Amyloid-PET quantification through the tracer-independent Centiloid (CL) scale has emerged as an essential tool for the accurate measurement of amyloid-β (Aβ) pathology in Alzheimer's disease (AD) patients. The AMYPAD consortium set out to integrate existing literature and recent work from the consortium to provide clinical context-of-use recommendations for the CL scale. Compared to histopathology, visual reads, and cerebrospinal fluid, CL quantification accurately reflects the amount of AD pathology. With high certainty, a CL value below 10 excludes the presence of Aβ pathology, while a value above 30 corresponds well with pathological amounts. Values falling in between these two cutoffs (“intermediate range”) are related to an increased risk of disease progression. Together, CL quantification is a valuable adjunct to visual assessments of amyloid-PET images. An abnormal amyloid biomarker assessment is a key criterion to determine eligibility for anti-amyloid disease-modifying therapies, and amyloid-PET quantification can add further value by precisely monitoring amyloid clearance, and hence guiding patient management decisions. Highlights: Centiloid (CL) quantification robustly reflects of the amount of Aβ pathology. CL &lt; 10/CL &gt; 30 reflects Aβ-negativity/positivity thresholds with high certainty. CL quantification is a valuable adjunct to visual assessments of amyloid-PET. CL quantification can support trial design and treatment management. CL quantification could support the identification of early or emerging Aβ pathology.</p>}},
  author       = {{Collij, Lyduine E. and Bollack, Ariane and La Joie, Renaud and Shekari, Mahnaz and Bullich, Santiago and Roé-Vellvé, Núria and Koglin, Norman and Jovalekic, Aleksandar and Garciá, David Valléz and Drzezga, Alexander and Garibotto, Valentina and Stephens, Andrew W. and Battle, Mark and Buckley, Christopher and Barkhof, Frederik and Farrar, Gill and Gispert, Juan Domingo}},
  issn         = {{1552-5260}},
  keywords     = {{Amyloid-β; Centiloid quantification; clinical trials; positron emission tomography}},
  language     = {{eng}},
  number       = {{12}},
  pages        = {{9037--9048}},
  publisher    = {{Wiley}},
  series       = {{Alzheimer's and Dementia}},
  title        = {{Centiloid recommendations for clinical context-of-use from the AMYPAD consortium}},
  url          = {{http://dx.doi.org/10.1002/alz.14336}},
  doi          = {{10.1002/alz.14336}},
  volume       = {{20}},
  year         = {{2024}},
}